BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9:354-75. [PMID: 27134665 DOI: 10.1177/1756283X16633050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23(36): 6593-6627 [PMID: 29085207 DOI: 10.3748/wjg.v23.i36.6593] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
2 Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Seifert B, Wensaas KA, Winchester C, de Wit N; European Society for Primary Care Gastroenterology. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther 2018;47:1054-70. [PMID: 29460487 DOI: 10.1111/apt.14539] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 18.0] [Reference Citation Analysis]
3 Nelkowska DD. Treating irritable bowel syndrome through an interdisciplinary approach. Ann Gastroenterol 2020;33:1-8. [PMID: 31892791 DOI: 10.20524/aog.2019.0441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Fragkos KC. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea. Clin Exp Gastroenterol 2017;10:229-40. [PMID: 28989282 DOI: 10.2147/CEG.S123621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
5 Shin CM, Choi YJ, Lee DH, Moon JS, Kim TY, Kim YK, Lee WH, Yoon H, Park YS, Kim N. Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement. Sci Rep 2021;11:13046. [PMID: 34158518 DOI: 10.1038/s41598-021-92007-3] [Reference Citation Analysis]
6 Seaman DR. Toxins, Toxicity, and Endotoxemia: A Historical and Clinical Perspective for Chiropractors. J Chiropr Humanit 2016;23:68-76. [PMID: 27920621 DOI: 10.1016/j.echu.2016.07.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Richardson DP, Ansell J, Drummond LN. The nutritional and health attributes of kiwifruit: a review. Eur J Nutr 2018;57:2659-76. [PMID: 29470689 DOI: 10.1007/s00394-018-1627-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 18.3] [Reference Citation Analysis]
8 Machelska H, Celik MÖ. Advances in Achieving Opioid Analgesia Without Side Effects. Front Pharmacol 2018;9:1388. [PMID: 30555325 DOI: 10.3389/fphar.2018.01388] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 15.7] [Reference Citation Analysis]
9 Gomaa E, Ayoub MM. Vardenafil oral jellies as a potential approach for management of pediatric irritable bowel syndrome. Saudi Pharm J 2021;29:955-62. [PMID: 34588841 DOI: 10.1016/j.jsps.2021.07.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Caes L, Orchard A, Christie D. Connecting the Mind-Body Split: Understanding the Relationship between Symptoms and Emotional Well-Being in Chronic Pain and Functional Gastrointestinal Disorders. Healthcare (Basel) 2017;5:E93. [PMID: 29206152 DOI: 10.3390/healthcare5040093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Hummel M, Knappenberger T, Reilly M, Whiteside GT. Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral hypersensitivity. World J Gastroenterol 2017; 23(33): 6065-6076 [PMID: 28970722 DOI: 10.3748/wjg.v23.i33.6065] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Karakula-Juchnowicz H, Gałęcka M, Rog J, Bartnicka A, Łukaszewicz Z, Krukow P, Morylowska-Topolska J, Skonieczna-Zydecka K, Krajka T, Jonak K, Juchnowicz D. The Food-Specific Serum IgG Reactivity in Major Depressive Disorder Patients, Irritable Bowel Syndrome Patients and Healthy Controls. Nutrients 2018;10:E548. [PMID: 29710769 DOI: 10.3390/nu10050548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
13 Getachew B, Aubee JI, Schottenfeld RS, Csoka AB, Thompson KM, Tizabi Y. Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties. BMC Microbiol 2018;18:222. [PMID: 30579332 DOI: 10.1186/s12866-018-1373-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
14 Di Guglielmo MD, Tonb D, He Z, Adeyemi A, van Golen KL. Pilot Study Measuring the Novel Satiety Hormone, Pro-Uroguanylin, in Adolescents With and Without Obesity. J Pediatr Gastroenterol Nutr 2018;66:489-95. [PMID: 29112082 DOI: 10.1097/MPG.0000000000001796] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]